Vemurafenib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3167 publications
Inhibitory effect of vemurafenib combined with panobinostat on human anaplastic thyroid cancer cells.
Journal: Pakistan journal of pharmaceutical sciences
Published: March 25, 2026
Development and Preliminary Evaluations of a Novel 18F-Labeled Tracer for Detection of BRAFV600E Mutant Status in Animal Models of Melanoma.
Journal: Molecular pharmaceutics
Published: March 13, 2026
Corrigendum to 'The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma': [Journal of Investigative Dermatology, Volume 135, Issue 5, May 2015, Pages 1368-1376].
Journal: The Journal of investigative dermatology
Published: March 13, 2026
Uveitis Associated with Protein Kinase Inhibitors in Cancer Patients: A Risk-Based Ophthalmologic Management.
Journal: Ocular immunology and inflammation
Published: March 13, 2026
Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.
Journal: Journal of proteome research
Published: February 25, 2026
Multiple opportunistic infections revealing Erdheim-Chester disease: an atypical presentation.
Journal: BMJ case reports
Published: February 19, 2026
Quaternary Phosphonium Salts Outperformed Vemurafenib (PLX) and Etoposide Against BRAFV600D,V600E PLX-Resistant Melanoma and MDR Neuroblastoma, Exhibiting No/Low Toxicity on 3T3/HaCaT Cells.
Journal: International journal of molecular sciences
Published: February 05, 2026
A New Combination Therapy Utilizing Mitochondria-Targeting Small-Molecule Ligands and Clinical Inhibitors against Melanoma.
Journal: ACS chemical biology
Published: January 21, 2026
Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers.
Journal: Life (Basel, Switzerland)
Published: January 14, 2026
Adipocyte-Derived Extracellular Vesicles Endow Melanoma Cells with Stem-like Traits via PGC-1α-Mediated Mitochondrial Reprogramming.
Journal: Antioxidants (Basel, Switzerland)
Published: January 12, 2026
Design, synthesis and antiproliferative, apoptotic, and immunomodulatory properties of new heteroaryl pyridine-linked 1,2,4-oxadiazoles as prospective dual EGFR/BRAFV600E inhibitors.
Journal: RSC advances
Published: January 08, 2026
An alginate-based 3D cell culture model as a useful tool for melanoma drug testing.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 20, 2025
Last Updated: 04/28/2026